Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meletios A Dimopoulos

Showing results (641-650 of 652) with videos related to

Pageof 66
Sort By:
The New England Journal of Medicine|December 9, 2025
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple MyelomaLuciano J Costa, Nizar J Bahlis, Aurore Perrot, et al.
The New England Journal of Medicine|December 12, 2023
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple MyelomaPieter Sonneveld, Meletios A Dimopoulos, Mario Boccadoro, et al.
Future Oncology (London, England)|September 17, 2024
A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myelomaPieter Sonneveld, Meletios A Dimopoulos, Mario Boccadoro, et al.
Lancet (London, England)|June 14, 2026
Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trialMeletios A Dimopoulos, Fredrik Schjesvold, Chengcheng Fu, et al.
The New England Journal of Medicine|June 30, 2021
Daratumumab-Based Treatment for Immunoglobulin Light-Chain AmyloidosisEfstathios Kastritis, Giovanni Palladini, Monique C Minnema, et al.
Nature Medicine|March 25, 2026
Enhanced dynamic risk stratification of smoldering multiple myelomaFloris Chabrun, Daniel E Schwartz, Susanna Gentile, et al.
Lancet (London, England)|November 15, 2020
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trialSebastian Grosicki, Maryana Simonova, Ivan Spicka, et al.
The New England Journal of Medicine|June 15, 2026
Talquetamab-Daratumumab in Relapsed or Refractory MyelomaRoberto Mina, Meral Beksac, Paula Rodríguez-Otero, et al.
The Lancet. Haematology|May 4, 2020
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 studyMichele Cavo, Francesca Gay, Meral Beksac, et al.
The Lancet. Oncology|March 4, 2021
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working GroupPhilippe Moreau, Shaji K Kumar, Jesús San Miguel, et al.
Pageof 66

Showing results (641-650 of 652) with videos related to

Sort By:
Pageof 66
The New England Journal of Medicine|December 9, 2025
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple MyelomaLuciano J Costa, Nizar J Bahlis, Aurore Perrot, et al.
The New England Journal of Medicine|December 12, 2023
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple MyelomaPieter Sonneveld, Meletios A Dimopoulos, Mario Boccadoro, et al.
Future Oncology (London, England)|September 17, 2024
A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myelomaPieter Sonneveld, Meletios A Dimopoulos, Mario Boccadoro, et al.
Lancet (London, England)|June 14, 2026
Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trialMeletios A Dimopoulos, Fredrik Schjesvold, Chengcheng Fu, et al.
The New England Journal of Medicine|June 30, 2021
Daratumumab-Based Treatment for Immunoglobulin Light-Chain AmyloidosisEfstathios Kastritis, Giovanni Palladini, Monique C Minnema, et al.
Nature Medicine|March 25, 2026
Enhanced dynamic risk stratification of smoldering multiple myelomaFloris Chabrun, Daniel E Schwartz, Susanna Gentile, et al.
Lancet (London, England)|November 15, 2020
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trialSebastian Grosicki, Maryana Simonova, Ivan Spicka, et al.
The New England Journal of Medicine|June 15, 2026
Talquetamab-Daratumumab in Relapsed or Refractory MyelomaRoberto Mina, Meral Beksac, Paula Rodríguez-Otero, et al.
The Lancet. Haematology|May 4, 2020
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 studyMichele Cavo, Francesca Gay, Meral Beksac, et al.
The Lancet. Oncology|March 4, 2021
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working GroupPhilippe Moreau, Shaji K Kumar, Jesús San Miguel, et al.
Pageof 66